The CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial investigated the effects of canagliflozin, an SGLT2 inhibitor, on renal outcomes in patients with type 2 diabetes and chronic kidney disease. The trial was conducted as a double-blind, randomized, placebo-controlled study involving 4401 patients with albuminuric chronic kidney disease and an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m². The primary outcome was a composite of end-stage kidney disease, doubling of serum creatinine, or death from renal or cardiovascular causes. The trial was stopped early after a planned interim analysis due to a significant reduction in the primary outcome rate in the canagliflozin group (30% lower risk) compared to the placebo group. Secondary outcomes, including cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure, were also significantly reduced in the canagliflozin group. The results suggest that canagliflozin may be an effective treatment option for renal and cardiovascular protection in patients with type 2 diabetes and chronic kidney disease.The CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial investigated the effects of canagliflozin, an SGLT2 inhibitor, on renal outcomes in patients with type 2 diabetes and chronic kidney disease. The trial was conducted as a double-blind, randomized, placebo-controlled study involving 4401 patients with albuminuric chronic kidney disease and an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m². The primary outcome was a composite of end-stage kidney disease, doubling of serum creatinine, or death from renal or cardiovascular causes. The trial was stopped early after a planned interim analysis due to a significant reduction in the primary outcome rate in the canagliflozin group (30% lower risk) compared to the placebo group. Secondary outcomes, including cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure, were also significantly reduced in the canagliflozin group. The results suggest that canagliflozin may be an effective treatment option for renal and cardiovascular protection in patients with type 2 diabetes and chronic kidney disease.